← Back to Clinical Trials
Recruiting NCT06473623

NCT06473623 Non-invasive Auricular Fiber Vagus Nerve Stimulation (afVNS) for Treatment of Autism Spectrum Disorder

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06473623
Status Recruiting
Phase
Sponsor Neuropix
Condition Autism Spectrum Disorder
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2025-12-01
Primary Completion 2026-02-01

Eligibility & Interventions

Sex All sexes
Min Age 7 Years
Max Age 26 Years
Study Type INTERVENTIONAL
Interventions
vagus nerve stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2025-12-01 with a primary completion date of 2026-02-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Non-invasive vagus nerve stimulation for the symptomatic improvements in Autism Spectrum Disorder

Eligibility Criteria

Inclusion Criteria: * Written informed consent * Age: between 7 and 26 years * Participants and parent/ guardian must have proficiency in English * Diagnosis of ASD as defined by ADOS-2 or DSM-5 criteria Exclusion Criteria: * Severe psychiatric disorders (e.g. bipolar, major depressive disorder) * Severe neurological disorders (e.g. stroke, epilepsy) * Bradyarrhythmia * History of head trauma (surgery or tumor) * Active medical implants (cochlear, VNS or pacemakers) * Cerebral shunts * Auricular skin disease that compromises placement of electrodes * Pregnancy

Contact & Investigator

Central Contact

Daniel Ko, PhD

✉ danielko@neuro-pix.com

📞 +85255308212

Principal Investigator

Daniel Ko, PhD

PRINCIPAL INVESTIGATOR

Neuropix

Frequently Asked Questions

Who can join the NCT06473623 clinical trial?

This trial is open to participants of all sexes, aged 7 Years or older, up to 26 Years, studying Autism Spectrum Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06473623 currently recruiting?

Yes, NCT06473623 is actively recruiting participants. Contact the research team at danielko@neuro-pix.com for enrollment information.

Where is the NCT06473623 trial being conducted?

This trial is being conducted at Tai Po, Hong Kong.

Who is sponsoring the NCT06473623 clinical trial?

NCT06473623 is sponsored by Neuropix. The principal investigator is Daniel Ko, PhD at Neuropix. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology